Skip to main content

Table 3 Clinical outcomes of patients with TB by DIH status

From: The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study

Characteristics

Total

(N = 168)

DIH

(n = 20)

Non-DIH

(n = 148)

P-value

Total treatment duration, days

243.4 ± 97.5

243.9 ± 81.5

243.3 ± 99.7

0.964

Actual treatment duration/planned treatment duration

1.14 ± 0.51

1.26 ± 0.48

1.13 ± 0.52

0.392

Treatment interruption period/total treatment duration

0.02 ± 0.06

0.04 ± 0.06

0.01 ± 0.04

<  0.001

Sputum culture conversion (solid) (n = 155)

155 (99.4)

20 (100.0)

135 (99.3)

0.587

Sputum culture conversion (liquid) (n = 162)

158 (98.1)

19 (100.0)

140 (97.9)

0.522

Time to sputum culture conversion (solid), days (n = 155)

47.0 ± 31.3

47.1 ± 26.1

47.0 ± 32.1

0.993

Time to sputum culture conversion (liquid), days (n = 162)

67.2 ± 96.8

64.0 ± 56.0

67.6 ± 101.2

0.859

2-month sputum culture conversion (solid) (n = 155)

129 (82.7)

16 (80.0)

113 (83.1)

0.787

2-month sputum culture conversion (liquid) (n = 162)

117 (73.1)

13 (68.4)

104 (73.8)

0.658

Treatment outcome

 Treatment completion

106 (63.1)

14 (70.0)

92 (62.2)

0.495

 Cure

54 (32.1)

3 (15.0)

51 (34.5)

0.080

 Treatment success

160 (95.2)

17 (85.0)

143 (96.6)

0.022

 TB-related mortality

0 (0)

0 (0)

0 (0)

1.0

 All-cause mortality

8 (4.8)

3 (15.0)

5 (3.4)

0.055

Recurrence within 1 year (n = 148)

7 (4.2)

2 (10)

5 (3.4)

0.196

  1. Data are presented as n (%) or mean ± SD. DIH drug-induced hepatotoxicity, TB tuberculosis